Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.
作者信息
Nazha Aziz, Sekeres Mikkael A, Komrokji Rami, Steensma David P, Kantarjian Hagop, Roboz Gail, Fenaux Pierre, Prebet Thomas, Azarnia Nozar, Zbyszewski Patrick S, Fruchtman Steven M, Santini Valeria, Silverman Lewis R, Platzbecker Uwe, Garcia-Manero Guillermo
机构信息
Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
出版信息
Blood Cancer J. 2017 Dec 14;7(12):644. doi: 10.1038/s41408-017-0018-7.
Abstract
摘要
Zotero 插件